Alembic Pharmaceuticals Q1FY26 PAT Rises 15% YoY to ₹154 Crore

Vadodara, August 5, 2025 – Alembic Pharmaceuticals Limited (NSE: APLLTD, BSE: 533573) reported a robust financial performance for Q1FY26. Alembic Pharmaceuticals’s consolidated net profit rose 15% year-on-year (YoY) to ₹154 crore. The 15% year-on-year surge was led by strong growth in international markets and steady performance in domestic formulations.

Key Financial Highlights (Consolidated)

• The company reported a 10% year-on-year increase in revenue, which stood at ₹1,711 crore in Q1 FY26, compared to ₹1,562 crore in the same period last year.
• EBITDA rose 20% to ₹288 crore, as against approximately ₹240 crore in Q1 FY25. The EBITDA margin for the quarter came in at 17%.
• Profit before tax (PBT) grew 21% year-on-year to ₹191 crore, up from ₹158 crore in the previous year.
• The company’s net profit (PAT) stood at ₹154 crore. This is a 15% increase from the ₹134 crore reported in Q1 FY25.

Management Commentary

“We began FY26 on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets. This growth reflects our strategic expansion and disciplined execution across geographies. Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains,” said Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited.

Segment-wise Revenue Performance

• India Formulations business reported ₹599 crore in revenue, registering a 5% year-on-year growth from ₹572 crore in Q1 FY25.
• Revenue from the US Generics segment rose 13% YoY to ₹523 crore, up from ₹461 crore.
• The Ex-US International Generics segment posted a strong 21% growth, with revenue increasing to ₹328 crore, compared to ₹271 crore a year ago.
• The API (Active Pharmaceutical Ingredients) segment remained flat, with revenue at ₹261 crore, marginally up from ₹259 crore last year.
• Total consolidated revenue for the quarter stood at ₹1,711 crore, reflecting a 10% year-on-year increase.

Operational Highlights

India Branded Business

• Domestic business posted a 5% YoY growth to ₹599 crore.
• Strong performance in Specialty Therapies including Gynaecology, Cardiology, Anti-Diabetics, Ophthalmology, and Animal Healthcare.
• Anti-infective and cough & cold therapies performed in line with market trends.
• 3 new products launched during the quarter.

International Business

• US Generics grew 13% YoY to ₹523 crore, supported by volume expansion.
• Company launched 4 new products in the US during Q1FY26.
• Ex-US Generics revenue rose 21% YoY to ₹328 crore.
• Received 6 ANDA approvals during the quarter, taking cumulative approvals to 223.

API Business

• API revenue saw a marginal 1% YoY growth to ₹261 crore.

Alembic Pharmaceuticals Stock Performance

Alembic Pharmaceuticals shares closed at ₹946, which is a 2.19% dip on August 5, 2025. Alembic Pharmaceuticals shares have dipped 20% in the last year, 9% in the year-to-date, and 5% in the previous month.

Alembic Pharmaceuticals Ltd opened at ₹980 and moved between an intraday high of ₹997 and a low of ₹940. The stock is trading between a 52-week high of ₹1,303.90 and a 52-week low of ₹725.20. The company has a market capitalisation of ₹18,570 crore and a P/E ratio of 31.87.

About Alembic Pharmaceuticals

Alembic Pharmaceuticals Limited is a research-driven pharmaceutical company based in Vadodara, India. The company develops, manufactures, and markets generic formulations and APIs. Its products are available in global markets. Alembic holds approvals from major regulators, including the US FDA. It is also a well-known name in India’s branded generics space.

REF: https://nsearchives.nseindia.com/corporate/APLLTD_05082025130836_Intimation_Press_Release_Signed.pdf

https://nsearchives.nseindia.com/corporate/APLLTD_05082025130156_APL_BM_Outcome_05082025.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations